---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-056786"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:57:57.502284+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences Q1 revenue $215.4M (+17% YoY); reaffirms FY2026 guidance >$1B

## Summary
- Q1 net product revenue $215.4M, up 17% YoY; diluted EPS $0.55 vs $0.78 in Q1 2025.
- Reaffirmed FY2026 WAKIX net revenue guidance of $1.0B-$1.04B; on track for >$1B.
- R&D expenses $69.4M (+101%) due to $32M upfront license payments; net income declined to $32.5M.
- Filed patent infringement suit vs AET Pharma/Sandoz; acquired exclusive license to pitolisant patent expiring 2042.
- Appointed Peter Anastasiou COO and Glenn Reicin CFO; cash and investments $870.5M as of March 31.

## SEC filing metadata
- accession: 0001104659-26-056786
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/0001104659-26-056786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-056786
- JSON: https://secwatch.observer/filing/0001104659-26-056786.json
- Plain text: https://secwatch.observer/filing/0001104659-26-056786.txt

## Source-grounded claims
- claim_id: bc436f0eaa7e0707846eaf563a9187e759cd7668
  claim: Harmony Biosciences Holdings, Inc. reported the quarter ended March 31, 2026 results: revenue $215.4 million. Guidance reaffirmed.
  evidence_excerpt: BIOSCIENCES REPORTS Q1 FINANCIAL RESULTS AND CONFIRMS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION; REINFORCES 2026 STRATEGIC PRIORITIES ​ WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion ​ Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/0001104659-26-056786-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.